Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL‑C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States

2007 ◽  
Vol 23 (9) ◽  
pp. 2125-2133 ◽  
Author(s):  
Kathleen M. Fox ◽  
Sanjay K. Gandhi ◽  
Robert L. Ohsfeldt ◽  
James W. Blasetto ◽  
Harold E. Bays
Keyword(s):  
Electronic Medical Records ◽  
Medical Records ◽  
National Cholesterol Education Program ◽  
Goal Attainment ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
The United States ◽  
Adult Treatment ◽  
Adult Treatment Panel ◽  
Low Density Lipoprotein Cholesterol

Ease: Ezetimibe Add-on to Statin for Effectiveness Trail

2006 ◽  
Vol 4 (1) ◽  
pp. 32-35
Author(s):  
Linda Brokes
Keyword(s):  
National Cholesterol Education Program ◽  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Absorption ◽  
Adult Treatment ◽  
Adult Treatment Panel ◽  
Community Based ◽  
Cholesterol Absorption Inhibitor ◽  
Additional Reduction

Results from the largest community-based clinical trial to date, involving more than 3000 patients, has shown that adding the cholesterol absorption inhibitor ezetimibe to ongoing stable statin therapy in patients with hypercholesterolemia produces a significant additional reduction in low-density lipoprotein (LDL)- cholesterol compared with adding a placebo.[1] In addition, more patients who added ezetimibe achieved their National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) If LDL-cholesterol targets. The Ezetimibe Add-on to Statin for Effectiveness (EASE) trial included a total of 3030 patients on a stable dose of a statin but not yet at their NCEP ATP III LDLcholesterel goal,[2]

Sign in / Sign up

Export Citation Format

Share Document